LL-37 vs TB4-Frag (TBF)
A side-by-side research comparison of LL-37 and TB4-Frag (TBF) across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | LL-37 | TB4-Frag (TBF) |
|---|---|---|
| Full name | Cathelicidin Antimicrobial Peptide LL-37 | Thymosin Beta-4 Fragment |
| Category | Healing & Recovery | Healing & Recovery |
| Status | Research compound | Research compound |
| Mechanism | Disrupts microbial membranes, neutralizes endotoxins, recruits immune cells via chemotaxis, and promotes angiogenesis and re-epithelialization. | Retains the actin-sequestering motif of full TB-4, promoting cell migration, angiogenesis, and reduction of inflammation at injury sites. The shorter sequence may offer improved bioavailability and targeted tissue penetration. |
| Molecular weight | 4493.33 Da | ~1,200-1,800 Da (fragment) |
| Half-life | ~4-6 hours | ~2-4 hours |
| Bioavailability | Variable by route; topical and injectable | High subcutaneous absorption |
| Typical dose | 50-100 mcg | 200-750 mcg per dose |
| Frequency | Daily | Daily or every other day |
| Route | Topical or subcutaneous injection | Subcutaneous injection |
LL-37 reported benefits
- Broad-spectrum antimicrobial
- Wound healing acceleration
- Biofilm disruption
- Immune system enhancement
TB4-Frag (TBF) reported benefits
- Wound and tissue healing
- Reduced inflammation
- Potential improved tissue penetration vs full TB-4
- Support for tendon and muscle repair
- Angiogenesis promotion
Related comparisons
Research and educational reference only. Not medical advice.